MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2016 International Congress

    The assessment of quality of life in patients with early and moderately advanced Huntington disease

    N. Szejko, L. Milanowski, A. Gogol, Z. Jamrozik, P. Janik (Warsaw, Poland)

    Objective: The aim of the study was to determine if available quality of life related scales are useful to detect the deterioration of quality of…
  • 2016 International Congress

    Enroll-HD: A global clinical research platform for Huntington’s disease

    T.A. Mestre, C. Fitzer-Attas, J. Giuliano, B. Landwehrmeyer, C. Sampaio (Ottawa, Canada)

    Objective: To provide an update on the global observational registry study of Huntington's disease (HD) included in Enroll-HD, a platform for HD clinical research. Background:…
  • 2016 International Congress

    Specific in-patient’s rehabilitation improves postural and gait instability in Huntington’s disease

    L. Brabcová, J. Roth, O. Horácek, M. Kolárová, H. Bozková, J. Rusz, P. Košková, K. Lísalová, F. Jancok, J. Klempír, E. Ruzicka, H. Brozová (Beroun, Czech Republic)

    Objective: To evaluate long-term effects of targeted rehabilitation on postural and gait stability in the early and middle stages of Huntington disease (HD). Background: HD…
  • 2016 International Congress

    Clinical and neuroimaging correlations in early manifest Huntington’s disease patients: Default mode network properties according to resting-state functional MRI

    Y.A. Seliverstov, E.V. Seliverstova, S.A. Klyushnikov, R.N. Konovalov, S.N. Illarioshkin (Moscow, Russia)

    Objective: (1) To compare pattern of spontaneous activity within default mode network (DMN) between early manifest Huntington's disease (HD) patients and healthy controls and (2)…
  • 2016 International Congress

    Epidemiology and economic burden of falls and fractures in patients with Huntington’s disease

    D.O. Claassen, P. Donga, S. Rajagopalan, L.M. De Boer, B. Carroll, S. Gandhi (Nashville, TN, USA)

    Objective: To assess epidemiology and economic burden of falls and fractures among Huntington's disease (HD) patients. Background: The clinical course of HD is characterized by…
  • 2016 International Congress

    Interleaved pro- and anti-saccade performance in Huntington’s disease

    I. Vaca-Palomares, J. Fernandez-Ruiz, B. Coe, D.P. Munoz (Kingston, ON, Canada)

    Objective: To investigate suppression of automatic movements and execution of voluntary motor commands in an early stage Huntington's disease patients. Background: The ability to suppress…
  • 2016 International Congress

    Predictors of quality of life in Huntington’s disease. A longitudinal observational study

    A. Brás, F. Júlio, M. Sousa, F. Blanco, C. Januário (Coimbra, Portugal)

    Objective: To analyze predictors and progression of quality of life in patients with Huntington's disease (HD), on a longitudinal assessment over two years. Background: HD…
  • 2016 International Congress

    Neurophysiological evidence of posterior-cortical alterations in premanifest Huntington’s: An event-related brain potentials study of face and face-like objects processing

    S. Martinez-Horta, J. Perez-Perez, A. Horta-Barba, R. Fernandez-Bobadilla, J. Pagonabarraga, J. Kulisevsky (Barcelona, Spain)

    Objective: To investigate the behavioral and neurophysiological correlates of face and face-like-object recognition in premanifest Huntington's disease (preHD). Background: PreHD provide an excellent framework to…
  • 2016 International Congress

    Alternatives for reducing chorea in Huntington disease, a long-term trial (ARC-HD): Updated week 8 results for the switch cohort

    V. Sung, D. Stamler, D.O. Claassen (Birmingham, AL, USA)

    Objective: To evaluate the sustained safety and efficacy following overnight switch from tetrabenazine (TBZ) to deutetrabenazine in patients with chorea associated with Huntington disease (HD).…
  • 2016 International Congress

    Evaluation of quality of life (QOL), patient- and clinician-reported outcomes with deutetrabenazine treatment of chorea in Huntington disease in first-HD

    C.M. Testa, D.O. Claassen, D. Oakes, D. Stamler, V. Sung, S. Frank, On behalf of the First-HD HSG Investigators (Richmond, VA, USA)

    Objective: To assess if deutetrabenazine treatment of chorea associated with HD resulted in changes in QoL, Patient Global Impression of Change (PGIC), or Clinical Global…
  • « Previous Page
  • 1
  • …
  • 1842
  • 1843
  • 1844
  • 1845
  • 1846
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley